Stockscreener 앱 받기
95.32
6.16%
-6.2417
전일 마감가:
$101.56
열려 있는:
$97.13
하루 거래량:
17.58M
Relative Volume:
1.51
시가총액:
$165.69B
수익:
$44.33B
순이익/손실:
$6.50B
주가수익비율:
25.64
EPS:
3.717
순현금흐름:
$7.40B
1주 성능:
-7.22%
1개월 성능:
-13.32%
6개월 성능:
-25.33%
1년 성능:
-26.52%
1일 변동 폭
$93.92
$99.00
1주일 범위
$93.92
$102.77
52주 변동 폭
$93.92
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
95.35 | 176.48B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
337.19 | 130.69B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.87 | 111.83B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
63.94 | 96.02B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.16 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott cuts profit forecast in wake of cancer screening deal - Crain's Chicago Business
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag - Proactive financial news
ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus
Earnings call transcript: Abbott Labs Q1 2026 results align with expectations - Investing.com India
Abbott Laboratories (ABT) Lowers Earnings Outlook Despite Revenue Growth - GuruFocus
Abbott Earnings Beat Estimates. Why the Stock Is Slumping. - Barron's
Transcript: Abbott Laboratories Q1 2026 Earnings Conference Call - Benzinga
Abbott Cuts 2026 Earnings Outlook Following First-Quarter Beat - marketscreener.com
Abbott trims 2026 profit forecast on Exact deal hit, shares fall - Reuters
Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know - TradingKey
Abbott cuts profit forecast in wake of cancer-screening deal - The Business Times
Stocks to Watch: TSMC, Abbott Laboratories, Netflix - WSJ
Abbott Laboratories Q1 Adjusted Earnings, Net Sales Rise; 2026 Adjusted EPS Guidance Lowered - marketscreener.com
These Stocks Are Today’s Movers: TSMC, Abbott, Hims & Hers, Schwab, Nvidia, J.B. Hunt, Voyager Tech, and More - Barron's
What Abbott Laboratories (ABT)'s First Illinois NEC Verdict Means For Shareholders - Yahoo Finance
Abbott Laboratories (ABT) Stock: Declines Despite 7.8% Revenue Growth and Strategic Expansion in Q1 - CoinCentral
Abbott Laboratories (NYSE:ABT) Releases Earnings Results, Meets Expectations - MarketBeat
Abbott (ABT) Q1 2026 Earnings Call Transcript - The Globe and Mail
Abbott Labs Topples On Post-Exact Sciences Guidance Update - Investor's Business Daily
Abbott (ABT) Beats Q1 Earnings and Revenue Estimates - Yahoo! Finance Canada
Abbott Laboratories stock price forecast: bearish momentum persists as ABT consolidates near support - Traders Union
Abbott: Q1 Earnings Snapshot - marketscreener.com
Abbott Laboratories (ABT) Reports Strong Q1 Revenue Growth, EPS In-Line - GuruFocus
Abbott (ABT) Adjusted EPS Forecast for Q2 Below Expectations - GuruFocus
Abbott stock tumbles on earnings. Nutrition business is struggling and merger costs biting. - MSN
Q1 progress positions Abbott for accelerating growth in 2026 - Abbott
PepsiCo climbs premarket; Abbott Laboratories, Travelers fall - Investing.com
Abbott reports Q1 earnings, completes Exact Sciences acquisition By Investing.com - Investing.com Canada
ABBOTT LABORATORIES ($ABT) Releases Q1 2026 Earnings - Quiver Quantitative
Abbott dips as Exact Sciences buyout hurts outlook (ABT:NYSE) - Seeking Alpha
Is Abbott Laboratories (ABT) Still 19.7% Undervalued After Q1 20 - GuruFocus
Abbott Laboratories Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Abbott Laboratories : Q1 2026 Earnings Infographic - marketscreener.com
Abbott Laboratories (NYSE:ABT) Releases FY 2026 Earnings Guidance - MarketBeat
Abbott Laboratories (ABT) Q1 2026 Results: Revenue Surpasses Expectations on Cancer Diagnostics Strength - Blockonomi
Abbott Laboratories’s (NYSE:ABT) Q1 CY2026 Sales Top Estimates - Yahoo Finance
Abbott shares dip on soft current-quarter guide; Q1 results in line - Investing.com
Abbott Laboratories stock ticks up after Q1 results and new cancer diagnostics business boost - Traders Union
Abbott Labs (ABT) Stock: Q1 Earnings Beat Revenue Estimates, Cancer Diagnostics Unit Boosts Results - CoinCentral
Abbott results beat on medical device boost, Exact deal hits forecast - marketscreener.com
Abbott Labs earnings matched, revenue topped estimates - Investing.com
Abbott Labs earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Abbott (ABT) Q1 2026 earnings rise on adjusted basis after Exact Sciences acquisition - Stock Titan
Abbott Cuts Profit Forecast in Wake of Cancer Screening Deal - Bloomberg.com
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences - Abbott MediaRoom
Earnings Flash (ABT) Abbott Laboratories Posts Q1 Adjusted EPS $1.15 per Share - marketscreener.com
Abbott Labs' Q1 sales up 7.8% to $11.16B - Breakingthenews.net
Abbott adds Exact Sciences, expands into fast-growing cancer tests - Stock Titan
Earnings Scheduled For April 16, 2026 - Benzinga
KBC Group NV Grows Position in Abbott Laboratories $ABT - MarketBeat
Will S&P 500 Open Up Or Down On April 16?Abbott Laboratories (NYSE:ABT) - Benzinga
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
자본화:
|
볼륨(24시간):